Pfizer (PFE) posts Q1 revenue of US$25.7bn as Comirnaty vaccine shines

2 min read | May 04, 2022 06:18 AM AEST | By Team Kalkine Media

Pfizer (PFE) posts Q1 revenue of US$25.7bn as Comirnaty vaccine shines — Image source: © Vonora | Megapixl.com

Pfizer on track to delivering 2 bn vaccine doses to poor nations

“We are on track to fulfill our commitment to deliver at least 2 billion doses to low- and middle-income countries in 2021 and 2022,” said Pfizer Chairman and CEO Albert Bourla.

The first-quarter performance is not only a proud achievement from a financial perspective but also from the standpoint of being a force to reckon with during the pandemic, he added.

Pfizer has a market cap of US$273.83 billion, a P/E ratio of 12.77, and a forward one-year P/E ratio of 6.66. Its EPS is US$3.85. The 52-week highest and lowest stock prices were US$61.71 and US$37.96, respectively. Its trading volume was 36,228,410 on May 2.

Pfizer’s 2022 revenue guidance remains the same and represents 27% operational growth from 2021 revenues at the midpoint.

During the first quarter of 2022, Pfizer returned US$4.2 billion to its shareholders through a combination of US$2.2 billion in cash dividends and US$2.2 billion in share repurchases.

Bottom line:

Pfizer’s direct sales of the Comirnaty vaccine grew to US$13.2 billion, driven by demand for booster doses. Pfizer also received several regulatory approvals that bolstered its sales.

Another key driver of revenue was Paxlovid, which contributed US$1.5 billion in global sales.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.